ANALYSIS OF NON-INVASIVE LIVER BIOMARKERS IN A PHASE I I TRIAL OF THE GLUCAGON AND GLP-1 RECEPTOR DUAL AGONIST SURVODUTIDE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS

被引：0

作者：

Noureddin, Mazen ^{[1
]}

Schoelch, Corinna ^{[2
]}

Bugianesi, Elisabetta ^{[3
]}

Alkhouri, Naim ^{[4
,5
]}

Fraessdorf, Mandy ^{[6
]}

Schattenberg, Joern ^{[7
]}

Newsome, Philip ^{[8
]}

Anstee, Quentin ^{[9
]}

Neff, Guy ^{[10
]}

Coxson, Harvey ^{[2
]}

Lawitz, Eric ^{[4
]}

Ratziu, Vlad ^{[11
]}

Nakajima, Atsushi ^{[12
]}

Hosseini-Tabatabaei, Azadeh ^{[13
]}

Sanyal, Arun ^{[14
]}

Younes, Ramy ^{[6
]}

机构：

[1] Houston Methodist Hosp, Houston, TX 77030 USA

[2] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[3] Univ Turin, Div Gastroenterol, Dept Med Sci, Turin, Italy

[4] Univ Texas Hlth San Antonio, Texas Liver Inst, San Antonio, TX USA

[5] Arizona Liver Hlth, Phoenix, AZ USA

[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[7] Saarland Univ, Dept Internal Med 2, Med Ctr, Homburg, Germany

[8] Univ Hosp Birmingham, Natl Inst Hlth Res, Biomed Res Ctr, Birmingham, W Midlands, England

[9] Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England

[10] Covenant Metab Specialists LLC, Sarasota, FL USA

[11] Sorbonne Univ, Inst Cardiometab & Nutr, Hop Pitie Salpetriere, Paris, France

[12] Yokohama City Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Yokohama, Kanagawa, Japan

[13] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[14] Virginia Commonwealth Univ, Richmond, VA 23284 USA

来源：

HEPATOLOGY | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

2647

引用

页码：S2005 / S2006

页数：2

共 34 条

[31] Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and bodyweight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial
Harrison, Stephen
Tomah, Shaheen
Suschak, John
Roberts, Scot
Yang, Jay
He, Liang
Georges, Bertrand
Rodwell-Green, Lakisha
Brown, Randy
Harris, M. Scott
Browne, Sarah
JOURNAL OF HEPATOLOGY, 2023, 78 : S54 - S55
[32] Diagnostic accuracy of two-dimensional shear wave elastography (2D-SWE) for non-invasive assessment of liver fibrosis in biopsyproven metabolic dysfunction-associated steatotic liver disease (MASLD). Systematic-review and multi-level random effects model meta-analysis
Taru, Madalina-Gabriela
Leucuta, Dan-Corneliu
Ferri, Silvia
Hashim, Ahmed
Orasan, Olga
Procopet, Bogdan
Lupsor-Platon, Monica
Turco, Laura
Stefanescu, Horia
Piscaglia, Fabio
Ravaioli, Federico
JOURNAL OF HEPATOLOGY, 2024, 80 : S521 - S521
[33] HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
Abdelmalek, Manal
Choi, Jaeduk
Kim, Youngmin
Seo, Kyounghee
Hompesch, Marcus
Baek, Seungjae
JOURNAL OF HEPATOLOGY, 2020, 73 : S124 - S124
[34] Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD)
Reis-Barbosa, Pedro H.
Mandarim-de-Lacerda, Carlos A.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2024, 38 (06) : 1059 - 1068

← 1 2 3 4 →